CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population
CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population
复制标题
DOI：
10.1089/dna.2006.25.287
复制
发表时间：
2006-05-01
影响因子：
3.1
通讯作者：
Mohan, Harsh
中科院分区：
文献类型：
--
作者：
Sobti, R. C.;Onsory, Khadijeh;Mohan, Harsh
为了研究CYP 17、SRD 5A 2、CYP 1B 1和CYP 2D 6变异体与前列腺癌的关系，对100例患者和相同数量的年龄匹配的对照男性进行了病例对照研究。携带一个CYP 17 A2等位基因拷贝的个体患前列腺癌的风险似乎无显著增加（OR，1.80; 95%CI，0.99-3.29，P = 0.05）。携带两个A2等位基因的个体患乳腺癌的风险增加（OR; 2.81，95%CI，1.06-7.40，P = 0.03）。与SRD 5A 2 k基因VV基因型男性相比，VL基因型与前列腺癌发病风险无显著相关性（OR; 0.54，95%CI; 0.29-1.03，P = 0.06）。LL基因型在对照组和前列腺癌患者中的发生率无差异（OR; 0.90，95%CI; 0.43-1.89，P = 0.79）。携带CYP 1B 1 Leu/瓦尔基因型的个体患前列腺癌的风险增加不显著（OR，1.70，95% CI，0.91-3.17，P = 0.09），而携带瓦尔/瓦尔等位基因的个体患前列腺癌的风险增加（OR，3.38; 95% CI，1.13-10.07，P = 0.02）。相对于CYP 2D 6基因野生型等位基因纯合子男性，患者中B等位基因杂合子的优势比为1.78（95%CI，0.76-4.17，P= 0.18），纯合子个体的优势比为1.95（0.55-6.93，P = 0.30）。这些观察结果表明，CYP 17 A2/A2、CYP 1B 1瓦尔/瓦尔和CYP 2D 6基因型可能与前列腺癌风险改变相关，而CYP 2D 6和SRD 5A 2 V89 L多态性与其在北印度人群中的风险无关。
To investigate the involvement of the CYP17, SRD5A2, CYP1B1, and CYP2D6 variants with prostate cancer, a case-control study of 100 patients and an equal number of age-matched control men was conducted. There appears to be a nonsignificant increase with risk of prostate cancer for individuals carrying one copy of the CYP17 A2 allele (OR, 1.80; 95% CI, 0.99-3.29, P = 0.05). The risk was increased in individuals having two A2 alleles ( OR; 2.81, 95% CI, 1.06-7.40, P = 0.03). Compared with men having the VV genotype of SRD5A2 kgene, there was no significant association between the VL genotype and the risk of prostate cancer (OR; 0.54, 95% CI; 0.29-1.03, P = 0.06). There was no difference in the occurrence of the genotype LL between controls and prostate cancer patients (OR; 0.90, 95% CI; 0.43-1.89, P = 0.79). There was a nonsignificant increased risk of prostate cancer for individuals carrying the CYP1B1Leu/Val genotype (OR, 1.70, 95% CI, 0.91-3.17, P = 0.09), which was increased in those having the Val/Val allele (OR, 3.38; 95% CI, 1.13-10.07, P = 0.02). Relative to men homozygous for the wild-type allele in CYP2D6 gene, those heterozygous for the B allele had an odds ratio of 1.78 (95% CI, 0.76-4.17, P= 0.18) for patients, and for homozygous individuals, it was 1.95 (0.55-6.93, P = 0.30). These observations have suggested that the CYP17 A2/A2, CYP1B1 Val/Val, and CYP2D6 genotypes may be associated with an altered risk of prostate cancer, while the CYP2D6 and SRD5A2 V89L polymorphism have no association with its risk in the North Indian population.